ANXA2 and pachyonychia congenita: The research mentioned above hints to the potential use of ANXA2 as a biomarker for the diagnosis and risk stratification of PC patients [104,105,106,108,111,112,113,114,115,117], as well as a supplement to their treatment [112,113,114,115,116].